Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Myeloma & selinexor in 2020

Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound. Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the use of selinexor for the treatment of multiple myeloma and provides an update on the latest data regarding the therapeutic. Highlighted are data from the BOSTON trial (NCT03110562), which investigated selinexor plus bortezomib plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with R/R multiple myeloma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Sagar Lonial, MD, has done consultancy work for Takeda, Celgene, BMS, Janssen, GSK, Abbvie, Novartis and Janssen; and has been a member of a board of directors for TG Therapeutics.